Key Takeaways:
Sino Biopharmaceutical Ltd.’s Class 1 innovative drug, Kumoxili Capsules, has received marketing approval from China's National Medical Products Administration (NMPA) for its second indication in treating advanced breast cancer.
The approval was announced by the company for the drug, a CDK2/4/6 inhibitor developed by its subsidiary Zhengda Tianqing. The new indication for Kumoxili, branded as Saitianxin, is for use in combination with fulvestrant for the initial endocrine therapy of patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
This marks the second approved indication for Kumoxili since its initial launch. The approval is based on positive clinical trial results, which demonstrated the drug's efficacy and safety for this patient population.
The expanded approval for Kumoxili is a significant development for Sino Biopharmaceutical, as it broadens the addressable market for the drug. This is expected to contribute to increased sales and strengthen the company's footprint in the competitive oncology market in China. Investors will be watching for the company's next earnings report to see the initial impact of the new indication on sales.
This article is for informational purposes only and does not constitute investment advice.
